In summary, our findings establish the FXR/HVEM axis as an immune evasion mechanism in PD-L1lo/– NSCLC, providing translational implications for future immunotherapy in this subgroup of patients. The gene discussed is TNFRSF14; the disease is non-small cell lung carcinoma.